Nuvectis Pharma, Inc. (NASDAQ: NVCT) initiates NXP900 Phase 1b program for advanced cancers. Successful completion of Phase 1a dose escalation study shows promising pharmacodynamic responses. Cash runway expected to support operations into 3Q-2027. Financial results for Q3 2025 show cash balance at $35.4 million, with a net loss of $7.5 million. Research and development expenses increased to $5.8 million. General and administrative expenses rose to $2.0 million.

Ron Bentsur, Chairman and CEO of Nuvectis, highlights progress in Phase 1b program for NXP900. Company’s goal is to demonstrate therapeutic potential as a single agent and in combination therapy. Completed Phase 1a dose escalation study and drug-drug interaction study in healthy volunteers. Cash balance increased to $35.4 million by the end of Q3 2025. Net loss for Q3 2025 was $7.5 million. Interest income was $0.3 million.

Nuvectis Pharma, Inc. focuses on precision medicines for serious conditions in oncology. Lead program, NXP900, is an oral small molecule inhibitor of SRC Family of Kinases. NXP900 Phase 1b program aims to showcase therapeutic potential. Financial results for Q3 2025 show cash balance at $35.4 million. Net loss for Q3 2025 was $7.5 million. Research and development expenses increased to $5.8 million.

Read more at GlobeNewswire: Nuvectis Pharma, Inc. Reports Third Quarter